Takeda’s Uloric Gets CV Death Warning And Restricted Indication, But No REMS
Executive Summary
Despite advisory committee pressure, US FDA stands firm against imposing REMS targeted at gout drug’s cardiovascular risks; however, Takeda must conduct utilization study to see if labeling changes impact prescribing patterns.
You may also be interested in...
Public Citizen Strikes Out In Call For Opioid Approval Moratorium After Recent Win
Petition was consumer advocacy group's first request for halt to approval of an entire drug class; Public Citizen has gotten full and partial approval of other recent petitions.
Do Black Boxes Work? US FDA Survey Would Test Impact On Prescribers
Depending on who you ask, black box warnings can fail to curb inappropriate prescribing or scare off patients who would benefit from an effective therapy. FDA is proposing a provider survey to find out what perceptions really are.
Do Black Boxes Work? US FDA Survey Would Test Impact On Prescribers
Depending on who you ask, black box warnings can fail to curb inappropriate prescribing or scare off patients who would benefit from an effective therapy. FDA is proposing a provider survey to find out what perceptions really are.